Please provide your email address to receive an email when new articles are posted on . Adults with diabetes with cardiomyopathy were at significantly higher risk for developing incident HF, according ...

Diabetes is a global health burden. A whopping 536 million people worldwide struggle with diabetes. Diabetic cardiomyopathy (DC) is a serious condition characterized by impaired heart function due to ...

Compared with placebo, a significant improvement in cardiac functional capacity was observed among caficrestat-treated patients not receiving concomitant SGLT2is or GLP-1 RAs. Treatment with ...

Diabetic cardiomyopathy describes a distinct myocardial dysfunction arising in the context of diabetes, independent of coronary artery disease or hypertension. Chronic hyperglycaemia and insulin ...

ATLANTA, GA — A multicenter controlled trial testing the ability of an aldose reductase inhibitor to stabilize early-stage asymptomatic diabetic cardiomyopathy missed its primary endpoint, researchers ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM), an independent diabetes complication, is characterized by abnormalities in ...

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which proceeds slowly and cannot be directly attributed to hypertension or other cardiovascular disorders.

Diabetic cardiomyopathy (DCM) is a progressive complication associated with type 2 diabetes (T2D), causing deterioration of cardiac function in diabetic patients, independent of coronary artery ...

AT-001 (also called caficrestat) is an investigational oral, novel, potent Aldose Reductase inhibitor in Phase 3 clinical development for the treatment of Diabetic Cardiomyopathy. The global ARISE-HF ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM), an independent diabetes complication, is characterized by abnormalities in ...